You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Diagnosing aggressive prostate cancer by spectroscopic photoacoustic tomography

    SBC: Vibronix, Inc.            Topic: 102

    DESCRIPTION provided by applicant Prostate cancer PCa is the No killer among male cancer patients The ultimate test is based on transrectal ultrasound guided needle biopsy and histological examination of fixed prostate tissues This conventional diagnostic procedure is invasive missing cases of cancer due to small sampling volume Moreover it leads to an overtreatment of patients du ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia

    SBC: MICROFLUIDIC INNOVATIONS, LLC            Topic: 102

    DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation To date small molecule inhibitors of MYC have been elusive An innovative approach would be to indirectl ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Asthmagram: objective assessment of asthma symptoms in children

    SBC: NeoVative, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Asthma is the most common chronic illness of childhood but many children have poorly controlled symptoms causing morbidities hospitalizations and costs The first step toward good asthma control is accurate assessment of symptoms Recall of the frequency and severity of symptoms is the cornerstone of asthma assessment Unfortunately recall by parents or ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Developing efficient and safe cell-permeable reprogramming peptides for generation of iPS cells.

    SBC: Vivoscript, Inc.            Topic: 200

    DESCRIPTION provided by applicant The groundbreaking discovery of induced pluripotent stem cells iPSCs has opened a new page for developing personalized cell based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells However the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alter ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Peptide Based Therapy for Lung Fibrosis

    SBC: Novici Biotech LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a biomimetic small molecule therapeutic for neovascular retinal diseases

    SBC: EyeMedix, Inc.            Topic: N

    DESCRIPTION provided by applicant Retinal diseases including age related macular degeneration AMD diabetic retinopathy DR diabetic macular edema DME and retina vein occlusion RVO are the leading causes of vision loss and blindness in people over years old According to the NEI in nearly million people in the U S suffered from some form of these diseases whose prevalen ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Paper-based Rapid Diagnostics for Early Dental Caries Prediction at the Chairside

    SBC: PHASE DIAGNOSTICS LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Dental caries is the single most common affliction across the globe affecting billion people The current process of identifying dental caries involves examining caries formation by naked eyes or X ray during routine checkups Once identified surgical restorative procedures are used to drill out the decay portion of the tooth an filled with synthetic mate ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Silica-Based Organic Polymer for Ambient Ionization Mass Spectrometry

    SBC: Prosolia, Inc.            Topic: NIGMS

    DESCRIPTION provided by applicant Most samples of chemical interest are complex mixtures making the usual combination of chromatography with mass spectrometry MS a natural choice However the increased demand for chemical analysis by mass spectrometry in many areas of science makes it imperative to increase efficiency of analysis by minimizing sample workup and overall analysis time which ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Novel Membrane Protein Solubilization/Stabilization Screen

    SBC: SOLUBLE THERAPEUTICS, INC            Topic: 100

    DESCRIPTION provided by applicant The increasing output of new integral membrane protein IMP structures is partially due to the availability of an increasing number of chemical variables such as detergents detergent like molecules lipids and solubilizing stabilizing additives It is clear that specific combinations and concentrations of these different variables are often necessary to impr ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government